Amfetamine controlled release (orally disintegrating tablet) - Neos Therapeutics

Drug Profile

Amfetamine controlled release (orally disintegrating tablet) - Neos Therapeutics

Alternative Names: Adzenys XR-ODT; Amfetamine polistirex; Amfetamine XR-ODT - Neos Therapeutics; Amphetamine extended-release - Neos Therapeutics; Amphetamine orally disintegrating tablet - Neos Therapeutics; Amphetamine XR-ODT - Neos Therapeutics; NT-0202

Latest Information Update: 08 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neos Therapeutics
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 15 Mar 2017 Neos Therapeutics plans three clinical trials for Attention-deficit hyperactivity disorder (In children, 4 to less than 6 years old) in USA
  • 16 May 2016 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO, 3.1mg, 6.3 mg, 9.4mg, 12.5mg, 15.7mg, 18.8mg) - First global launch
  • 27 Jan 2016 Registered for Attention-deficit hyperactivity disorder (In children, In adolescents, In adults) in USA (PO, 3.1mg, 6.3 mg, 9.4mg, 12.5mg, 15.7mg, 18.8mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top